Company / Accounts Receivable
SUTRO BIOPHARMA, INC. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$4.0M
FY2025
5-year range
$4.0M / $36.1M
FY2021-FY2025
Trend
-53.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 8 years, ranging from $2M in FY2018 to $36M in FY2023.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -6.5%.
Declined from $36M to $4M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -17.7%
- 5-Year CAGR
- -6.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -6.5%, indicating a declining trend.
- In FY2025, accounts receivable decreased 53.8% year-over-year.
- Peak accounts receivable was recorded in FY2023.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0M | -53.8% |
| FY2024 | $8.6M | -76.1% |
| FY2023 | $36.1M | +406.6% |
| FY2022 | $7.1M | -42.8% |
| FY2021 | $12.5M | +124.0% |
| FY2020 | $5.6M | -11.7% |
| FY2019 | $6.3M | +153.0% |
| FY2018 | $2.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026